INCYTE Executive and Leadership Team

Bill Meury, the Chief Executive Officer at INCYTE, directs the overarching corporate strategy and long-term vision for the biopharmaceutical organization. Overseeing the commercialization of critical oncology therapeutics like JAKAFI and Iclusig, the Chief Executive Officer ensures alignment between research initiatives and market demands. This leadership role involves managing complex stakeholder relationships and driving sustainable growth within the competitive pharmaceutical landscape. By prioritizing the development of kinase inhibitors, Bill Meury directly impacts the company's ability to address unmet medical needs for patients with myelofibrosis and leukemia. Meury maintains a focus on operational efficiency and scientific integrity, ensuring that the organization remains at the forefront of therapeutic innovation. Through strategic resource allocation and executive oversight, Meury secures the company's position as a leader in the biopharmaceutical sector, consistently delivering value to patients and shareholders alike.

Suky Upadhyay, the Executive Vice President & Chief Financial Officer at INCYTE, manages the financial health and capital allocation strategies of the organization. Overseeing fiscal planning, investor relations, and budgetary controls, the Executive Vice President & Chief Financial Officer ensures that resources support the discovery and commercialization of oncology therapeutics. This leadership role involves balancing the high costs of clinical development with the need for consistent revenue growth from products like JAKAFI. By optimizing the capital structure and maintaining rigorous financial oversight, Suky Upadhyay directly impacts the company's ability to fund future research and development projects. Upadhyay collaborates with the executive team to evaluate market opportunities and mitigate financial risks associated with the biopharmaceutical sector. Through disciplined financial management, Upadhyay secures the necessary funding to sustain long-term growth and innovation, ensuring the company remains financially resilient while pursuing its mission to improve patient outcomes.

Andrew Blyton, the Vice President & Chief Information Officer at INCYTE, architects the digital infrastructure and data security frameworks necessary for modern biopharmaceutical operations. Overseeing the integration of advanced analytics and information systems, the Vice President & Chief Information Officer ensures that clinical research data remains secure and accessible for global development teams. This leadership role involves modernizing the technological backbone of the company to support rapid drug discovery and commercial scaling. By implementing robust cybersecurity protocols and scalable cloud solutions, Andrew Blyton directly impacts the efficiency of internal research processes. Blyton manages the digital transformation roadmap, ensuring that information technology aligns with the broader mission of delivering life-saving treatments. Through the optimization of enterprise software and data management systems, Blyton provides the essential digital foundation required for the company to maintain its competitive edge in the pharmaceutical industry.

Steven Stein, the Executive Vice President & Head Chief Medical Officer, Late-Stage Development at INCYTE, directs the clinical progression and regulatory strategy for late-stage therapeutic candidates. Overseeing the transition of drug candidates from clinical trials to commercial availability, the Executive Vice President & Head Chief Medical Officer, Late-Stage Development ensures that all medical research meets the highest standards of safety and efficacy. This leadership role involves managing interactions with regulatory bodies and guiding the clinical development of kinase inhibitors for complex cancers. By supervising the late-stage pipeline, Steven Stein directly impacts the speed and success of bringing new treatments to market. Stein coordinates with research teams to validate clinical data and support the therapeutic efficacy of the company's portfolio. Through expert medical oversight and strategic clinical planning, Stein ensures that the organization successfully navigates the complexities of late-stage development, ultimately expanding the reach of life-saving oncology treatments.